Share Name Share Symbol Market Type Share ISIN Share Description
C4x Discovery Holdings Plc LSE:C4XD London Ordinary Share GB00BQQ2RV18 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 33.00 121,322 08:35:25
Bid Price Offer Price High Price Low Price Open Price
33.10 34.20 34.00 33.00 33.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -5.91 -1.96 75
Last Trade Time Trade Type Trade Size Trade Price Currency
08:33:00 O 25,000 34.40 GBX

C4x Discovery (C4XD) Latest News

More C4x Discovery News
C4x Discovery Investors    C4x Discovery Takeover Rumours

C4x Discovery (C4XD) Discussions and Chat

C4x Discovery Forums and Chat

Date Time Title Posts
24/1/202218:04C4X Discovery Holdings plc2,746

Add a New Thread

C4x Discovery (C4XD) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all C4x Discovery trades in real-time

C4x Discovery (C4XD) Top Chat Posts

C4x Discovery Daily Update: C4x Discovery Holdings Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker C4XD. The last closing price for C4x Discovery was 33p.
C4x Discovery Holdings Plc has a 4 week average price of 33p and a 12 week average price of 28.75p.
The 1 year high share price is 52p while the 1 year low share price is currently 26.50p.
There are currently 226,712,697 shares in issue and the average daily traded volume is 628,596 shares. The market capitalisation of C4x Discovery Holdings Plc is £74,815,190.01.
alloa2003: Savvy investors will start picking up cheap stock now - whoever "managed" this sale over the last week or so doesnt have a clue. They have smashed a share price and set the rumour mill going again.
alloa2003: They dont hang around:- 21 December 2021 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces the appointment of Dr Catherine Jane Tralau-Stewart, PhD, FRSC, as Chief Scientific Officer ("CSO"), as of 4 January 2022. This lady seems to have the perfect track record to assist in developing C4XD. All of the pieces of the jigsaw are falling into place. If you read Clive Dix comments, he mentions they are looking at DNA related treatments now because they will soon have the current portfolio of molecules commercialised. Interesting stuff! Remember, royalty payments are on top of milestone payments and would turn this into a cash cow if just 1 or 2 molecules make it to market - let alone more!
alloa2003: Good solid results and plenty of little nuggets in there to keep investors interested but not the biggy I was personally expecting. Interesting to see they have made plans to conserve cash in the event that trials are extended, etc and they wont need to raise any more funds. I think C4XD is on the verge of becoming self-funding which is a massive step forward and should remove the previously constant threat of a fund raising. Interesting to see this element of the announcement about the previous fund raising:- Successful £15.0 million fundraise (before expenses) with a total of 107,142,858 Placing Shares and 99,169,286 Warrants issued to new and existing shareholders I believe the warrant strike price is 29p so if ever they needed additional funding these warrants could be exercised by, I would guess, mostly institutional shareholders - circa £30m. Dilutive but a useful drop back to have if they ever needed cash for any reason. All in all, steady as she goes I think and we await further developments within some of the very interesting historic and new areas mentioned.
bloomberg2: ("C4XD", "C4X Discovery" or the "Company")Clive Dix receives the Scrip Lifetime Achievement Award 20213 December 2021 - C4X Discovery Holdings plc (AIM: C4XD), is delighted to announce that its Chief Executive Officer, Dr Clive Dix together with Dame Kate Bingham, the leaders of the UK Vaccine Taskforce, have won the Lifetime Achievement Award at the 2021 Scrip Awards. The Scrip Awards applaud the essential role that the pharmaceutical, biotech and other allied industries play in improving healthcare.Eva-Lotta Allan, Chairman of C4X Discovery, said: "We are very proud of this significant achievement by both Clive and Kate and we are thankful for the incredibly important work that they and the whole of the UK Vaccine Taskforce have carried out. Throughout his impressive career, Clive has contributed significantly to the industry and to us, at C4XD, his drive and determination to best serve patients is what makes Clive the great leader and CEO that he is and everyone at C4XD is delighted to see them all recognised through the Scrip Lifetime Achievement Award."
alloa2003: In my experience, people of this calibre do not move to tinpot companies. So I can only assume there are great plans for the future of C4XD - the share price is suggesting that!
bloomberg2: C4X Discovery Holdings plc("C4XD", "C4X Discovery" or the "Company")C4X Discovery CEO, Clive Dix, receives OBN Special Recognition Award 202126 November 2021 - C4X Discovery Holdings plc (AIM: C4XD), is honoured to announce that CEO, Dr Clive Dix has received the Special Recognition Award at the OBN 2021 Awards for his life-long contribution to the UK life sciences industry.Eva-Lotta Allan, Chairman of C4X Discovery, commented: "The prestigious OBN Awards celebrate the very best of UK life science. We are therefore very proud of all that Clive has achieved throughout his career, and in particular, here at C4XD. Clive is a veteran of the UK biotechnology industry with more than 30 years of experience, with a strong track record as a serially successful entrepreneur and an experienced pharmaceutical R&D executive. He has the scientific expertise, industry experience and leadership qualities that are needed to grow companies in such a challenging industry. Over the past year, in addition to his corporate work, Clive has played a leading role in the UK Vaccine Taskforce which has been recognised as leading one of the most successful rollouts of the COVID-19 vaccination globally. Clive is an inspiration to us here at C4XD and it is wonderful to see the recognition across the industry for all his contributions to our thriving life sciences sector."
alloa2003: As people have mentioned on numerous occassion - if for example the INDV molecule made it to market, that would cost INDV a potential maximum £219m ($294) in payments (plus royalties on top I believe) to C4XD, then we have the other bigger deal and an even bigger one in the pipeline. C4XD currently has a market value of £100m so INDV taking out C4XD at double the share price would be cost neutral and give them free exposure to the other deal signed and future deals. Its is all starting to hot up, this one could go anywhere
1aconic: The full INDV trial results are (according to INDV) expected to be published by the end of their Q4. By my reckoning that's means before the end of Jan 2022. However, they've already announced that the phase one was promising and have already moved onto phase 2. What we don't however know is what milestone payments are triggered between phase one and phase two. C4XD are in a very healthy cash position at the moment and I don't personally see a scenario where another diluting fund raise would be needed in the next couple of years just for general expenses. However, the market might be prepared to give it a chunky re-rate if there was another healthy injection of cold hard cash from the INDV project milestone or another of the pipeline molecules being licensed. To my mind, that's one option for what's moving the share price currently. Also, C4XD seems currently to be very reasonably valued for an increasingly proven Biotech... you just have to compare it to the likes of Exsciencia for proof of that. All Clive Dix would have to do in the next results is to drop "progress with AI led technologies" into the report and you'd need a re-rate of 10x here to make it comparible to peers.
the stigologist: Perfectly normal for Deputy Chair of UK Vaccine Taskforce to speak to Bill Gates Interestingly Bill Gates is one of biggest investors in Schrodinger (SDGR) Mkt Cap $5bn Schrodinger is the nearest equivalent to C4XD IF C4XD share price doesn't go up soon I can see a US Company snapping them up for 100p+ The Indivior deal alone at $294m makes C4XD cheap at 100p (c.£130m Mkt Cap) Clive today told us the NRF2/IL17/a4B7 projects have similar potential
alloa2003: Nice update with a mention of work in the area of Covid-19:- 25 August 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today provides a business update. Clive Dix, CEO of C4XD, commented: "I am delighted to share the progress we have made over recent months across our proprietary portfolio despite the challenges of the COVID-19 pandemic, in particular, the continued headway in our key inflammation programmes. Importantly, Indivior recently commenced a Phase 1 clinical trial with our selective Orexin-1 antagonist, C4X_3256, for the treatment of opioid dependence and we eagerly await those results in due course. Our two most advanced programmes, NRF-2 and IL-17, continue to move forward with one of our lead NRF-2 molecules, C4X_6746, showing significant efficacy in a pre-clinical model of Inflammatory Bowel Disease (IBD). This enables expansion of our commercial discussions beyond those partners already engaged in assessing the programme for Pulmonary Arterial Hypertension and Sickle Cell Disease. "We are also pleased to announce a new partnership with the GEN-COVID Consortium in Italy. The collaboration will utilise Taxonomy3® to examine genetic data from a significant number of COVID-19 patients to identify genes specifically associated with severe COVID-19 disease. The disease continues to spread throughout the world and a clear understanding of how it affects people differently remains elusive. We believe that genetics may play a role in explaining the differences in an individual's disease susceptibility, severity and prognosis. This is a new area for C4XD and we are excited to be working on such an important project. We remain committed to deliver and drive novel small molecule drugs against challenging targets towards clinical development." C4XD has continued to make progress across key programmes in its portfolio: · Indivior has commenced a Phase 1 clinical trial for C4XD's novel selective Orexin-1 antagonist, C4X_3256 (also known as INDV-2000), for the treatment of opioid dependence with the first patient now dosed (hxxps://www.clinicaltrials.gov/ct2/show/NCT04413552). This single ascending dose study in healthy volunteers is anticipated to complete by year end. · One of C4XD's lead NRF-2 activator molecules C4X_6746, has recently been shown to significantly inhibit the disease score in a pre-clinical model of IBD in a dose-related manner. Candidate nomination studies continue. · The lead optimisation stage has been initiated for C4XD's novel oral IL-17 inhibitor programme for the treatment of Psoriasis with the aim of identifying further improved small molecules to drive towards a pre-clinical candidate shortlist. We note that Leo Pharma A/S has recently announced that it has identified the first oral IL-17 inhibitor IND-ready candidate with clinical studies expected to be initiated soon. This provides further confidence that the challenge of developing a small molecule alternative to injectable monoclonal antibodies to target IL-17 can be achieved and there has been increased interest from potential pharma partners. · Significant progress has been made on C4XD's early oral inhibitor programme targeting a4b7 integrin for the treatment of IBD. Effective antibody therapy against this target is already approved, removing the clinical target risk, but effective oral therapy remains highly sought after. C4XD has identified a second series of novel, potent and selective inhibitors providing a further competitive edge for this programme. This reaffirms the capability of C4XD's Conformetrix technology to discover novel chemical scaffolds for high-value challenging drug targets. Both series have recently demonstrated oral bioavailability in PK studies with the current focus on improving PK properties to demonstrate functional inhibition of a4b7 integrin in vivo following oral dosing. · The LifeArc risk-share collaboration on an oral small molecule inhibitor programme for the treatment of haematological cancers and inflammatory disease continues to progress well despite being impacted by COVID-19. Three novel series have been identified by harnessing C4XD's Conformetrix technology and recent data has demonstrated functional cell activity and oral bioavailability for all three series. Optimisation continues with the aim of demonstrating functional inhibition of the target in vivo following oral dosing. · C4XD has recently entered a new collaboration with the GEN-COVID consortium, a network of more than 20 hospitals in Italy led by Professor Alessandra Renieri of the University of Siena. The collaboration will use the unique mathematical genetic analysis methodology of Taxonomy3® to investigate the role genetics plays in the widely varied disease susceptibility, severity and prognosis observed between individuals with COVID-19. Taxonomy3® will analyse genetic data from a significant number of COVID-19 positive patients collected by the consortium to identify genes associated with severe COVID-19 disease. The aim is to identify a unique genetic signature that can successfully predict mild vs. severe disease to inform treatment of patients at risk. The analysis may also uncover novel biology driving severity of the disease which may inform potential novel drug targets for treatment.
C4x Discovery share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
C4x Discov..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220125 08:52:04